A case study demonstrates that affinity chromatography can offer efficiency and scalability for gene therapy manufacturing using viral vectors.
On Nov. 2, 2012, UniQure’s Glybera, an AAV-1 based drug, was approved in Europe for use in adult patients diagnosed with familial lipoprotein lipase deficiency (LPLD). Since then, interest in gene therapies has skyrocketed, with a fourfold increase in the number of gene therapies being developed between 2012 and 2015. With the power to overcome genetic disorders, these therapies could prove revolutionary to the field of medicine.
The technology aims to treat diseases by delivering genetic material encoding a protein with a therapeutic effect into a patient’s cells. In most gene-therapy studies, a carrier molecule or a vector must be used to deliver the therapeutic gene to the target cells. There are a number of molecular vectors and techniques available for use; however, most frequently this is achieved with viruses.
Download the
BioPharm International’s 2017 Development Strategies for Emerging Therapies eBook.
BioPharm International
eBook: Development Strategies for Emerging Therapies
Vol. 30
September 2017
Pages: 27–30
When referring to this article, please cite it as O. Terova et al., "Affinity Chromatography Accelerates Viral
Vector Purification for Gene Therapies," BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
2 Commerce Drive
Cranbury, NJ 08512